The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes
Event:
ESC Congress 2022
Topic:
Anticoagulants
Session:
Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities